Novartis AG (XSWX:NOVNEE) Cyclically Adjusted PS Ratio: (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NOVNEE Novartis AG XSWX:NOVNEE
80 GF Score
Price CHF119.30
GF Value CHF98.69
! 7 Warning Signs
View Full Analysis

What is Novartis AG Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG  (XSWX:NOVNEE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novartis AG Cyclically Adjusted PS Ratio Related Terms


Novartis AG Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted PS Ratio Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.84 3.88 4.11 4.25 5.19

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.53 4.72 5.19 5.67 5.89

XSWX:NOVNEE vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PS Ratio falls into.


XSWX:NOVNEE
80GF Score
Novartis AG XSWX:NOVNEE
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novartis AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Novartis AG's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.263/108.5400*108.5400
=6.263

Current CPI (Jun. 2026) = 108.5400.

Novartis AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.002 99.604 5.451
201612 5.368 99.380 5.863
201703 4.940 100.040 5.360
201706 5.097 100.285 5.517
201709 5.178 100.254 5.606
201712 2.692 100.213 2.916
201803 4.509 100.836 4.854
201806 4.918 101.435 5.262
201809 4.716 101.246 5.056
201812 5.041 100.906 5.422
201903 4.900 101.571 5.236
201906 5.092 102.044 5.416
201909 5.383 101.396 5.762
201912 5.416 101.063 5.817
202003 5.319 101.048 5.713
202006 4.799 100.743 5.170
202009 4.983 100.585 5.377
202012 5.068 100.241 5.488
202103 5.211 100.800 5.611
202106 5.345 101.352 5.724
202109 5.473 101.533 5.851
202112 1.885 101.776 2.010
202203 5.324 103.205 5.599
202206 5.742 104.783 5.948
202209 4.814 104.835 4.984
202212 4.734 104.666 4.909
202303 4.823 106.245 4.927
202306 5.048 106.576 5.141
202309 5.242 106.570 5.339
202312 4.910 106.461 5.006
202403 5.238 107.355 5.296
202406 5.623 107.991 5.652
202409 5.505 107.468 5.560
202412 6.020 107.128 6.099
202503 6.081 107.722 6.127
202506 6.155 108.075 6.181
202509 5.892 107.710 5.937
202512 5.702 107.200 5.773
202603 5.580 108.060 5.605
202606 6.263 108.540 6.263

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Novartis AG (XSWX:NOVNEE) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of CHF119.30 is trading 20.9% above its estimated GF Value™ of CHF98.69.

Key valuation signals for XSWX:NOVNEE:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: CHF98.69 vs. price of CHF119.30 (20.9% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the XSWX:NOVNEE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score

Get the complete analysis for XSWX:NOVNEE

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF119.30
Price
CHF98.69
GF Value